Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722140 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Commercial Insight: Antipsychotics - From Blockbuster Brands to Billion Dollar Generics
Datamonitor, Dec 2004, Pages: 173


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction

Second Generation Antipsychotics (SGAs) continue to drive the antipsychotic market with a growth rate of 27.2% between 2002-2003, yielding revenues of over $9.5 billion in 2003 responsible for a 93.3% share of the market. However, several patent expiries and product launches are set to send the market through a period of change.

Scope

Overview of current market including profiles of key brands and key events impacting each brand during 2003-2004

Assessment of current and future opportunities and threats in the antipsychotics market across the seven major pharmaceutical markets

Global sales for leading antipsychotic products from 1999-2003 are presented, with projections for future performance up to 2014

In-depth discussion of assumptions and events used in forecast analysis

Highlights

With an increasingly crowded schizophrenia market, SGA manufacturers are seeking to add new indications to their products labeling, capitalizing on the existing high off-label. Already, the majority of SGAs are approved for bipolar mania, and many have or are in the process of gaining approval for bipolar maintenance, as well as other niche areas.

Zyprexa, the market leading SGA, is currently experiencing patent challenges from numerous generics manufacturers. Datamonitor believes it is likely that Lilly will prevail in the courts, although, if generic incursion occurs in 2005, the SGA market could look very different.

The extreme interest in this market place by generics manufacturers is unsurprising. The SGA market currently includes three blockbuster brands with Abilify joining this select club in 2005. Datamonitor forecasts that three of the generic molecules will see blockbuster revenues by 2013.

Reasons to Purchase

Quantify future size and scope of antipsychotics market and potential for new products

Understand key drivers to this market and predict future performance of these compounds

Identify hot areas of the market not targeted by competitors


Customers who bought this item also bought

Chinese Markets for Polybutadiene Rubber (BR)

Br Malls Participacoes Sa

Br. Holdings Corporation

The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective

The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran

The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus

The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria

The 2009 Import and Export Market for Butadiene Rubber (BR) in Uruguay

The 2009 Import and Export Market for Butadiene Rubber (BR) in China

The 2009 Import and Export Market for Butadiene Rubber (BR) in India

The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia

The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds